The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multimodal profiling of biliary tract cancers to detect potentially actionable biomarkers and differences in immune signatures between subtypes.
 
Kabir Mody
Stock and Other Ownership Interests - CytoDyn; Oncotherapeutics
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Genentech/Roche; Ipsen; Merrimack; Vicus Therapeutics
Research Funding - Agios; ARIAD; ArQule; AstraZeneca (Inst); Basilea (Inst); FibroGen; Gritstone Bio (Inst); Incyte (Inst); MedImmune; Merck (Inst); Senhwa Biosciences; Taiho Pharmaceutical; TRACON Pharma; Turnstone Bio (Inst); Vyriad (Inst)
 
Nilofer Saba Azad
Honoraria - AMAG Pharmaceuticals; QED Therapeutics
Consulting or Advisory Role - AMAG Pharmaceuticals; Dava Oncology; QED Therapeutics; Taiho Pharmaceutical
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); Bayer; Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group; EMD Serono; Genentech (Inst); Incyte; Intensity Therapeutics (Inst); Merck (Inst); Syndax (Inst)
 
Prerna Jain
Employment - Tempus
 
Sherif El-Refai
Employment - Tempus
Stock and Other Ownership Interests - Tempus
 
Rachna T. Shroff
Consulting or Advisory Role - Agios; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Debiopharm Group; Exelixis; Incyte; Merck; QED Therapeutics; Taiho Pharmaceutical
Research Funding - Exelixis; Halozyme; Merck; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Taiho Pharmaceutical
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exact Sciences; Genentech/Roche; Gilead Sciences; Merck (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche/Genentech
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Merck
 
Denise Lau
Employment - Tempus
Stock and Other Ownership Interests - Tempus
Research Funding - Tempus
Patents, Royalties, Other Intellectual Property - Tempus
Travel, Accommodations, Expenses - Tempus
 
Gregory B. Lesinski
Consulting or Advisory Role - ProDa
Research Funding - Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Vaccinex (Inst)
 
Mark Yarchoan
Consulting or Advisory Role - Eisai; Exelixis; Geneos
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)